Public Companies
Filament Health To Host Virtual Investor Update
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it will…
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Wednesday, October 19, 2022 at 2:00 p.m. Eastern (11:00 a.m. Pacific).
During the event, Chief Executive Officer (CEO) Benjamin Lightburn and Chief Science Officer (CSO) Ryan Moss will discuss Filament’s recent progress including intellectual property developments, a successful financing, an FDA-approved clinical trial in partnership with the University of California San Francisco, and plans for future growth.
The discussion will be followed by a question-and-answer session with the Company’s senior management team.
A recording of the webcast will be available on the investor section of the Company’s website following the event.
About Filament Health
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics6 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics6 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics5 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics5 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics5 days ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?
-
Ketamine4 days ago
DEA poised to move cannabis to Schedule III